Moos, Walter H.Maneta, EleniPinkert, Carl A.Irwin, Michael H.Hoffman, Michelle E.Faller, Douglas V.Steliou, Kosta2020-05-142016-03-01Walter H Moos, Eleni Maneta, Carl A Pinkert, Michael H Irwin, Michelle E Hoffman, Douglas V Faller, Kosta Steliou. 2016. "Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia." Drug Development Research Volume 77, Issue 2, pp. 53 - 72. https://doi.org/10.1002/ddr.212950272-43911098-2299https://hdl.handle.net/2144/40859Please note: this work is permanently embargoed in OpenBU. No public access is forecasted for this item. To request private access, please click on the locked Download file link and fill out the appropriate web form.Neuropsychiatric disorders are a heterogeneous group of conditions that often share underlying mitochondrial dysfunction and biological pathways implicated in their pathogenesis, progression, and treatment. To date, these disorders have proven notoriously resistant to molecular-targeted therapies, and clinical options are relegated to interventional types, which do not address the core symptoms of the disease. In this review, we discuss emerging epigenetic-driven approaches using novel acylcarnitine esters (carnitinoids) that act on master regulators of antioxidant and cytoprotective genes and mitophagic pathways. These carnitinoids are actively transported, mitochondria-localizing, biomimetic coenzyme A surrogates of short-chain fatty acids, which inhibit histone deacetylase and may reinvigorate synaptic plasticity and protect against neuronal damage. We outline these neuroprotective effects in the context of treatment of neuropsychiatric disorders such as autism spectrum disorder and schizophrenia.p. 53 - 72en-USScience & technologyLife sciences & biomedicineChemistry, medicinalPharmacology & pharmacyAutismBipolarButyrateCarnitinoidsEpigeneticHistone deacetylaseNeurodegenerativeNeurodevelopmentalNeuropsychiatric disordersPMX-500Parkinson diseaseSchizophreniaPMX-550Histone deacetylase inhibitorsAlpha-lipoic acidElectron-transport chainGene-environment interactionsNMDA receptor dysfunctionLong-term potentiationLamb rennet pasteSpectrum disordersNeurodevelopmental disordersAlzheimer diseaseMitochondrial dysfunctionAnimalsAutism spectrum disorderCarnitineEpigenomicsNeuroprotective agentsMitochondriaHumansAntioxidantPharmacology and pharmaceutical sciencesArticle10.1002/ddr.212950000-0002-5530-3194 (Steliou, Kosta)62168